Table 1.
Prospective randomized trials of perioperative therapy for locally advanced esophageal squamous cell carcinoma
| Study | Author | Year | Histology | Treatment | n | Five‐year survival rate | P‐value |
|---|---|---|---|---|---|---|---|
| JCOG9204 7 | Ando et al | 2003 | SCC | Post‐CF | 120 | 55% (DFS) | .037 |
| Surgery alone | 122 | 45% (DFS) | |||||
| OEO2 9 | Allum et al | 2009 | AC/SCC | Pre‐CF | 320 | 23.0% (OS) | .03 |
| 66.5%/30.8% | Surgery alone | 335 | 17.1% (OS) | ||||
| JCOG9907 10 | Ando et al | 2012 | SCC | Pre‐CF | 164 | 55% (OS) | .04 |
| Post‐CF | 166 | 43% (OS) | |||||
| NCT012255231 3 | Zhao et al | 2015 | SCC | Peri‐PCF | 175 | 31% (RFS) | <.001 |
| Pre‐PCF | 171 | 17% (RFS) | |||||
| TROG 14 | Burmeister et al | 2005 | AC/SCC | Pre‐CRT | 128 | 22.2 mo (median OS) | NS |
| 62%/37% | Surgery alone | 128 | 19.3 mo (median OS) | ||||
| CROSS 15 | van Hagen et al | 2012 | AC/SCC | Pre‐CRT | 178 | 47% (OS) | .003 |
| 75%/23% | Surgery alone | 188 | 34% (OS) | ||||
| JCOG1109 16 (ongoing) | ‐ | ‐ | SCC | Pre‐CF | ‐ | ‐ | |
| Pre‐DCF | ‐ | ‐ | |||||
| Pre‐CRT | ‐ | ‐ |
Abbreviations: AC, adenocarcinoma; DFS, disease‐free survival; NS, not significant; OS, overall survival; Peri‐PCF, perioperative paclitaxel + CDDP +5‐FU; Post‐CF, postoperative CDDP + 5‐FU; Pre‐CF, preoperative CDDP + 5‐FU; Pre‐CRT, preoperative chemoradiotherapy; Pre‐DCF, preoperative docetaxel + CDDP +5‐FU; Pre‐PCF, preoperative paclitaxel + CDDP +5‐FU; RFS, relapse‐free survival; SCC, squamous cell carcinoma.